Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesTransplantUpper Ohio Valley Pancreatic Islet Coverage | Open…
    Ask Trek AI about this page
    CurrentHealth Plan of the Upper Ohio Valley, Inc.Policy N/A

    Pancreatic Islet Cell Transplantation

    Customize your policy alerts

    Sign up for all healthplanofupperohiovalley policy alerts

    Know when healthplanofupperohiovalley releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical necessity for allogeneic and autologous pancreatic islet cell transplantation, including covered indications, investigational or non-covered services, and applicable billing codes. It applies to Health Plan of the Upper Ohio Valley members and providers across all lines of business.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyPancreatic Islet Cell Transplantation
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective Date1/24/2026
    Next Review Date12/10/2026
    Key ActionDocument the applicable medical necessity criteria in the medical record, including transplant type, clinical criteria, immunosuppression plan, renal transplant history, and infusion count.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Maximum allogeneic infusions
    18+Minimum age for covered allogeneic transplantation

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Type 1 diabetes
    Covered allogeneic indication
    Severe chronic pancreatitisCovered autologous indication
    4Excluded or non-covered service categories

    Covered and Non-Covered Services

    Allogeneic pancreatic islet transplantation

    Allogeneic pancreatic islet transplantation is covered when ALL of the following are met.

    Eligibility and clinical criteria

    • Age: Member is 18 years of age or older18 years or older
    • Diabetes and hypoglycemia: Member has type 1 diabetes and is unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and educationType 1 diabetes; repeated severe hypoglycemia despite intensive management and education
    • Immunosuppression: Lantidra will be used in conjunction with concomitant immunosuppression therapy, such as mycophenolate mofetil, sirolimus, or tacrolimusConcomitant immunosuppression required
    • Renal transplant history: Member has not received a renal transplantNo prior renal transplant
    • Infusion limit: Administration has not exceeded a maximum of 3 infusions or transplantsMaximum 3 infusions/transplants

    Repeat allogeneic infusion

    A repeat Lantidra infusion may be covered when ALL of the following are met.

    Repeat infusion requirements

    • Initial approval criteria: Member meets all initial approval criteria for allogeneic pancreatic islet transplantation
    • Timing and insulin independence: Member has not achieved independence from exogenous insulin within one year of the infusion or has lost independence from exogenous insulin within one year after a previous infusionWithin 1 year of infusion or within 1 year after loss of insulin independence
    • Total infusion limit: The repeat infusion does not cause total administration to exceed 3 infusions or transplantsMaximum 3 infusions/transplants

      The policy states that there are no data regarding effectiveness or safety for more than 3 infusions.

    Autologous pancreatic islet transplantation

    Autologous pancreatic islet transplantation may be considered medically necessary when ALL of the following are met.

    Clinical indication and surgical use

    • The transplant is used as an adjunct to a total or near-total pancreatectomy in an individual with severe chronic pancreatitis that cannot be managed by other treatmentsSevere chronic pancreatitis; total or near-total pancreatectomy; other treatments inadequate

    Allogeneic islet cell transplantation using the FDA-approved cellular therapy product donislecel-jujn (Lantidra) is considered investigational for type 1 diabetes when the applicable coverage criteria are not met.

    The following services are excluded and non-covered: bioartificial pancreas devices, ex-situ machine pancreas perfusion for pancreas transplantation in hypothermic or normothermic settings, and pancreatic islet xenotransplantation.

    Islet transplantation is excluded when requested for situations other than the covered indications, including increased longevity or a lifestyle preference such as a desire to no longer take insulin.

    Allogeneic pancreatic islet transplantation is considered investigational and not medically necessary when the member does not meet every applicable criterion, including the requirements for age, type 1 diabetes with repeated severe hypoglycemia despite intensive management and education, concomitant immunosuppression, no prior renal transplant, and no more than 3 infusions (transplants). It is also not medically necessary for other indications.

    Autologous pancreatic islet cell transplantation is considered investigational and not medically necessary when it is not performed as an adjunct to total or near-total pancreatectomy for severe chronic pancreatitis that cannot be managed by other treatments, or when requested for another indication.

    Transplant Candidate Requirements

    Allogeneic islet transplant candidate

    Allogeneic pancreatic islet transplantation candidates must meet ALL of the following criteria.

    Allogeneic candidate requirements

    • Member is 18 years of age or older18 years or older
    • Member has type 1 diabetes and is unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and educationType 1 diabetes; repeated severe hypoglycemia despite intensive management and education
    • Lantidra will be used in conjunction with concomitant immunosuppression therapy, such as mycophenolate mofetil, sirolimus, or tacrolimusConcomitant immunosuppression required

    Exclusion Criteria

    Prior renal transplant is an exclusion criterion for covered allogeneic pancreatic islet transplantation. Coverage is also excluded when administration would exceed 3 total allogeneic infusions or transplants; the policy notes that effectiveness and safety data are not available beyond three infusions.

    Billing and Procedure Coding

    Islet cell transplant procedure codesCPT
    0584TIslet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous.
    0585TIslet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic.
    0586TIslet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open.
    G0341Percutaneous islet cell transplant, includes portal vein catheterization and infusion.
    G0342Laparoscopy for islet cell transplant, includes portal vein catheterization and infusion.
    G0343Laparotomy for islet cell transplant, includes portal vein catheterization and infusion.
    S2102Islet cell tissue transplant from pancreas; allogeneic.
    Lantidra product and alternative billing codesHCPCS
    No Specific codeDonislecel-jujn (Lantidra; CellTrans Inc).
    J3590Unclassified biologics; billing option for Lantidra when needed.
    C9399Unclassified drugs or biologicals; billing option for Lantidra when needed.
    Maximum allogeneic infusion count
    Maximum allogeneic infusions/transplants3 total infusions (transplants)
    Applicable therapyLantidra allogeneic pancreatic islet cellular therapy
    Evidence limitationThere is no data regarding effectiveness or safety for more than 3 infusions
    Repeat Lantidra timing
    Repeat-infusion eligibilityMember meets all initial approval criteria
    If insulin independence is not achievedRepeat infusion may occur within one year of the prior infusion

    Documentation and Denial Risks

    Documentation Required

    Medical Necessity Documentation

    The medical record must include documentation that reflects the applicable medical-necessity criteria. Records are subject to audit by THP at any time pursuant to the terms of the provider agreement.

    Documentation Required

    Clinical Criteria Support

    Document the clinical facts supporting the requested transplant type and coverage criteria, including the member’s age, diabetes type, repeated severe hypoglycemia despite intensive diabetes management and education, and inability to approach target HbA1c when applicable.

    • For allogeneic transplantation, document age 18 or older, type 1 diabetes, severe hypoglycemia, intensive diabetes management and education, concomitant immunosuppression, renal-transplant status, and the number of prior infusions.
    • For autologous transplantation, document severe chronic pancreatitis, failure of other treatments, and that the transplant is adjunctive to a total or near-total pancreatectomy.

    Pancreatic Islet Cell Transplantation

    Pancreatic islet cell transplantation involves infusion of insulin-producing pancreatic islet cells, commonly into the portal vein of the liver. Allogeneic transplantation uses donor cells and requires concomitant immunosuppression, while autologous transplantation uses the individual's own islet cells and may be performed with pancreatectomy for otherwise medically refractory severe chronic pancreatitis.

    Policy Definitions

    Autologous
    SourceCells or tissues obtained from the same individual
    Transplant typeAutologous cellular transplantation uses the patient's own cells or tissues
    Related procedureAutologous islet cell transplantation involves infusion of the patient's own pancreatic islet cells
    Allogeneic transplantation
    Donor relationshipGenetically non-identical donor of the same species
    Transplantation typeTransplantation of islet cells from that donor
    Policy-specific source
    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyPancreatic Islet Cell Transplantation
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective Date1/24/2026
    Next Review Date12/10/2026
    Key ActionDocument the applicable medical necessity criteria in the medical record, including transplant type, clinical criteria, immunosuppression plan, renal transplant history, and infusion count.
    SourceLink
    On This Page
    Covered and Non-Covered ServicesTransplant Candidate RequirementsExclusion CriteriaBilling and Procedure CodingDocumentation and Denial RisksPancreatic Islet Cell TransplantationPolicy Definitions
  1. Member has not received a renal transplantNo prior renal transplant
  2. The member has not exceeded 3 total allogeneic infusions or transplantsMaximum 3 infusions/transplants
  3. Autologous islet transplant candidate

    Autologous pancreatic islet transplantation may be considered when ALL of the following apply.

    Autologous candidate requirements

    • The individual has severe chronic pancreatitis that cannot be managed by other treatments, and autologous islet transplantation is performed as an adjunct to a total or near-total pancreatectomySevere chronic pancreatitis; total or near-total pancreatectomy; other treatments inadequate
    If insulin independence is lost
    Repeat infusion may occur within one year after loss of independence from exogenous insulin following a previous infusion
    Total administration limitAdministration may not exceed 3 infusions (transplants)
    Denial Risk

    Allogeneic Criteria Not Met

    Allogeneic pancreatic islet transplantation is investigational and not medically necessary when every applicable coverage criterion is not met or for other indications.

    • Member must be at least 18 years old and have type 1 diabetes with inability to approach target HbA1c because of repeated severe hypoglycemia despite intensive diabetes management and education.
    • Lantidra must be used with concomitant immunosuppression; the member must not have received a renal transplant; and administration must not exceed three infusions.
    • A repeat infusion requires that all initial approval criteria remain satisfied and that insulin independence was not achieved within one year of infusion or was lost within one year after a prior infusion.
    Denial Risk

    Autologous Criteria Not Met

    Autologous pancreatic islet transplantation is investigational and not medically necessary when it does not meet the covered indication or for other indications.

    • The procedure must be medically necessary as an adjunct to a total or near-total pancreatectomy in an individual with severe chronic pancreatitis that cannot be managed by other treatments.
    Denial Risk

    Explicitly Excluded Services

    Do not submit requests for services expressly excluded or non-covered under the policy.

    • Bioartificial pancreas devices (BAP).
    • Ex-situ machine pancreas perfusion for pancreas transplantation, whether hypothermic or normothermic.
    • Pancreatic islet xenotransplantation.
    • Islet transplantation in situations other than the covered indications.
    Denial Risk

    Lifestyle or Longevity Indication

    Islet transplantation is non-covered when the primary indication is to increase longevity or address lifestyle preferences rather than a covered medical indication.

    • Requests intended to increase longevity.
    • Requests motivated by lifestyle issues, including a desire to no longer take insulin.
    For this policy, the cells are from human cadaver donors
    Bioartificial device (BAP)
    Intended durationIntended for long-term use
    Biological componentCombines living insulin-secreting cells or islets
    Synthetic component and purposeUses a synthetic membrane or capsule to create a hybrid therapy for long-term blood glucose regulation
    Ex-situ machine pancreas
    DurationShort-term process
    PurposeEvaluates or treats a donor pancreas outside the body before transplantation
    Perfusion methodA machine perfuses the donor pancreas with a warm, oxygenated solution outside the body
    Islet cell auto-transplantation
    Cell sourceThe patient's own pancreatic islet cells
    ProcedureInfusion of those cells into the portal vein
    Anatomic destinationThe portal vein of the liver
    Islet cell
    Cell typeA pancreatic cell
    Hormones producedHormones such as insulin and glucagon
    Physiologic roleThe hormones are secreted into the bloodstream and help control blood glucose